bioXXmed AG (HAM:T5O) ROE % Adjusted to Book Value: -4.61% (As of Dec. 2025)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Valuation Possible Value Trap

3 Warning Signs

View Full Analysis

What is bioXXmed AG ROE % Adjusted to Book Value?

bioXXmed AG HAM:T5O 33 ROE % Adjusted to Book Value is -4.61% as of Dec. 2025. GuruFocus rates HAM:T5O with a GF Score™ of 33/100 and a GF Value™ of €9.07 (Possible Value Trap). The stock has 3 warning signs investors should review.

bioXXmed AG's ROE % for the quarter that ended in Dec. 2025 was -692.06%. bioXXmed AG's PB Ratio for the quarter that ended in Dec. 2025 was 150.00. bioXXmed AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -4.61%.

bioXXmed AG ROE % Adjusted to Book Value Related Terms

bioXXmed AG ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for bioXXmed AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

bioXXmed AG ROE % Adjusted to Book Value Chart

bioXXmed AG Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-18.55

-16.92

-23.43

-45.29

-1.52

bioXXmed AG Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-46.83	-12.71	-106.60	-28.50	-4.61

HAM:T5O vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, bioXXmed AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bioXXmed AG ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, bioXXmed AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where bioXXmed AG's ROE % Adjusted to Book Value falls into.

Save Embed

33GF Score

bioXXmed AG HAM:T5O

ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

bioXXmed AG ROE % Adjusted to Book Value Calculation

bioXXmed AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-228.13%	/	150.00
	=	-1.52%

bioXXmed AG's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-692.06%	/	150.00
	=	-4.61%

Frequently Asked Questions Learn more about ROE % Adjusted to Book Value →

What does a ROE % Adjusted to Book Value of -4.61% mean?

bioXXmed AG (HAM:T5O) has a ROE % Adjusted to Book Value of -4.61% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on bioXXmed AG and its competitors.

Is bioXXmed AG's ROE % Adjusted to Book Value too high?

bioXXmed AG's current ROE % Adjusted to Book Value is -4.61%. Overall, bioXXmed AG has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does bioXXmed AG's ROE % Adjusted to Book Value compare to VRTX and REGN?

bioXXmed AG's ROE % Adjusted to Book Value of -4.61% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROE % Adjusted to Book Value for a Biotechnology company?

A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROE % Adjusted to Book Value mean?

A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on bioXXmed AG and its competitors. bioXXmed AG's current ROE % Adjusted to Book Value is -4.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is bioXXmed AG stock overvalued right now?

Based on GuruFocus' analysis, bioXXmed AG (HAM:T5O) is currently considered Possible Value Trap. The stock's GF Value™ is €9.07, compared to a current price of €0.77 — trading 91.5% below its estimated fair value. The current ROE % Adjusted to Book Value is -4.61%. bioXXmed AG's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROE % Adjusted to Book Value calculated?

ROE % Adjusted to Book Value is calculated from a company's financial statements. For bioXXmed AG (HAM:T5O), the current ROE % Adjusted to Book Value is -4.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is bioXXmed AG (HAM:T5O) Overvalued in 2026?

Based on GuruFocus' analysis, bioXXmed AG stock appears to be undervalued. The current stock price of €0.77 is trading 91.5% below its estimated GF Value™ of €9.07. GuruFocus considers bioXXmed AG to be Possible Value Trap.

Key valuation signals for HAM:T5O:

ROE % Adjusted to Book Value: -4.61%
GF Value™: €9.07 vs. price of €0.77 (91.5% below fair value)
GF Score™: 33/100 with 3 warning signs

No single metric tells the full story. See the HAM:T5O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

bioXXmed AG Business Description

Industry Healthcare Biotechnology

Comparable Companies FRA:9RP VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA XKRX:068270 RPRX ROIV BNTX INCY INSM HKSE:02269 ASND HKSE:01801

Other Exchanges T5O:Germany

Address Riedstrasse 2, Darmstadt, HE, DEU, 64295

Website https://www.bioxxmed.ag

bioXXmed AG is an investment and holding company in the technology sector. It originated from CytoTools GmbH, a successful German technology enterprise from the pharmaceuticals and medical products field.

33GF Score

Get the complete analysis for HAM:T5O

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77

Price

€9.07

GF Value

View HAM:T5O Analysis

See ROE % Adjusted to Book Value data for all stocks →